|[October 15, 2013]
SetPoint Medical Named One of the "Fierce 15" Leading Medical Technology Companies of 2013
VALENCIA, Calif. --(Business Wire)--
Medical, a biomedical technology company developing neuromodulation
therapies for inflammatory diseases, announced today that it has
been named by FierceMedicalDevices as
one of 2013's Fierce 15 device and diagnostic companies, designating it
as one of the most promising private companies in the med tech space.
This is FierceMedicalDevices' second annual Fierce 15
"These companies represent some of the best and brightest in the device
and diagnostics industries today," FierceMedicalDevices Editor
Damian Garde said. "They'll be producing big things in the months ahead."
"We are honored to be selected as a Fierce 15 company," said Anthony
Arnold, chief executive officer of SetPoint Medical. "SetPoint
embodies the innovative spirit of this award as we advance our
breakthrough approach, using neuromodulation to provide physicians and
patients with new and innovative treatments for rheumatoid arthritis
(RA), Crohn's disease and other autoimmune and inflammatory diseases."
The Fierce 15 celebrates the spirit of being "fierce" - championing
innovation and creativity, even in the face of intense competition.
SetPoint is developing a novel
proprietary bioelectronic medicine platform to treat a variety of
inflammation-mediated autoimmune diseases. In contrast to
immunosuppressive drugs, this neuromodulation therapy uses an
implantable pulse generator to stimulate the vagus nerve, activating the
body's natural Inflammatory
Reflex to produce a systemic anti-inflammatory effect.
An internationally recognized newsletter reaching more than 30,000
medical device and diagnostics industry professionals, FierceMedicalDevices provides
subscribers with an authoritative analysis of the day's top stories.
Every year, FierceMedicalDevices evaluates dozens of
private companies from around the world for its annual Fierce 15 list,
which is based on factors including technology strength, partnerships,
venture backers and a competitive market position.
A complete list of "Fierce 15" companies - the online newsletter's
second annual selection - is available online at
FierceMedicalDevices is the med tech industry's daily
monitor - a free email newsletter and web resource providing the latest
news, articles and resources related to M&A, clinical trials, FDA
approval and regulation, and more. Signing up is free.
About SetPoint Medical
Medical is a privately held biomedical technology company dedicated
to treating patients with debilitating inflammatory diseases using
proprietary implantable neuromodulation
devices. SetPoint's approach is intended to offer patients and providers
approach for the treatment of RA and other chronic inflammatory
diseases with less risk and cost than drug therapy.
SetPoint's novel platform consists of an implantable miniature
neuromodulation device, wireless charger and iPad prescription pad
application. The system uses vagus nerve stimulation to activate the
body's natural Inflammatory
Reflex, which produces a potent systemic anti-inflammatory effect.
The company presented positive results from a first-in-human open-label
proof-of-concept trial in rheumatoid arthritis at the American College
of Rheumatology annual meeting in November 2012. The results confirmed
extensive preclinical studies and showed clinical efficacy comparable to
leading immunosuppressive drugs. SetPoint is headquartered in Valencia,
Ca., and current investors in the company include Morgenthaler Ventures,
Foundation Medical Partners, Topspin Partners, Covidien Ventures, Action
Potential Venture Capital Limited, the GlaxoSmithKline (GSK) new
strategic venture capital fund for bioelectronic medicines and
technologies, and Boston Scientific. For more information, visit www.setpointmedical.com.
[ Back To Technology News's Homepage ]